Showing 2 results for Moghaddami Tabrizi N
Moghaddami Tabrizi N, Eazadi Mood N, Tahmasbi M,
Volume 59, Issue 4 (9 2001)
Abstract
The pre-eclampsia/eclampsia is one of the commonest conditions peculiar to pregnancy, to describe the occurrence of hypertension, proteinuria and edema in pregnancy. It is about seven times more frequent in first gestation and uncommon before 20 week's gestation. Serum BhCG levels were prospectively determined in 260 midtrimester singleton pregnancies where admitted from October 1999 until September 2000 at Mirza Kouchak Khan hospital, prenatal clinic. Obstetric chart review was undertaken after delivery to identify cases in which pre eclampsia developed. The median maternal age was 26.0 years, and the median gestational age at the time of blood collection was 19.0 weeks. Of these, 17 cases (6.5 percent) had pre eclampsia. The median level of the BhCG was 35060.5 mlu/ml in those with pre eclampsia, whereas that in those without pre eclampsia was 33755.1 mlu/ml. The difference was not significant (P=0.28). Although elevated midtrimester serum BhCG levels in clinically normal patients was reported in severaly pre eclampsia women, this is not a good test for early detection of mild pre eclampsia.
Eftekhar Z, Mohagheghi S, Yarandi F, Izadi Mood N, Moghaddami Tabrizi N, Rezaee Z,
Volume 64, Issue 11 (7 2006)
Abstract
Background: Endometrial cancer is the most common malignancy of genital system which is commonly seen after menopause. Rises in the age of marriage non-surgical methods, using systemic progestins, have been evaluated to treat the young patients with well-differentiated endometrial cancer who wish to preserve their fertility.
Methods: Twenty one infertile patients with stage Ia well-differentiated endometrial adenocarcinoma were enrolled in a quasi-experimental study. The treatment initiated with 160mg/d of megestrol acetate then continued with 320mg/d for non-responsive cases. Patients follow up with FD&C and hysteroscopy. Patients divided in two groups on the basis of response to therapy and persistent. The responsive patients were introduced to IVF group and evaluated for later fertility and birth of alive newborns for three years.
Results: This study showed a response rate of 85.71% and 14.29% undergoing TAH. The mean duration of treatment was 5.85±2.00 month. The response to therapy was observed in 27.78% with dose of 160mg/d and the remaining patients with 320mg/d. Pregnancy occurred in 27.78%, 2 of which ended up in a term delivery and the others ended before term. Recurrence happened in 16.67% that 66.67% of them experienced remission again.
Conclusion: Use of 320mg/d seems to be associated with a better therapeutic response. Serious complications were not observed with this dose. Furthermore, continuance of the drug for three month following a normal pathology report was decreased the rate of recurrence.
